scholarly journals Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogeneFNDC3B

Cell Cycle ◽  
2012 ◽  
Vol 11 (9) ◽  
pp. 1773-1781 ◽  
Author(s):  
Chunlin Cai ◽  
Megha Rajaram ◽  
Xin Zhou ◽  
Qing Liu ◽  
John Marchica ◽  
...  
Keyword(s):  
Multiple Cancer ◽  
Cancer Pathways ◽  
Tumor Maintenance

scholarly journals Multiple cancer pathways regulate telomere protection

2019 ◽  
Vol 11 (7) ◽  
Author(s):  
Leire Bejarano ◽  
Giuseppe Bosso ◽  
Jessica Louzame ◽  
Rosa Serrano ◽  
Elena Gómez‐Casero ◽  
...  
Keyword(s):  
Multiple Cancer ◽  
Cancer Pathways ◽  
Telomere Protection

Strategic Combination Therapies for Ovarian Cancer

2020 ◽  
Vol 20 (8) ◽  
pp. 573-585
Author(s):  
Xinran Li ◽  
Angel S.N. Ng ◽  
Victor C.Y. Mak ◽  
Karen K.L. Chan ◽  
Annie N.Y. Cheung ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapies ◽  
Cancer Biology ◽  
Gynecologic Cancer ◽  
Antiangiogenic Agents ◽  
Combination Therapies ◽  
Multiple Cancer ◽  
Therapeutic Modalities ◽  
Cancer Pathways ◽  
Effective Combination

Ovarian cancer remains the leading cause of gynecologic cancer-related deaths among women worldwide. The dismal survival rate is partially due to recurrence after standardized debulking surgery and first-line chemotherapy. In recent years, targeted therapies, including antiangiogenic agents or poly (ADP-ribose) polymerase inhibitors, represent breakthroughs in the treatment of ovarian cancer. As more therapeutic agents become available supplemented by a deeper understanding of ovarian cancer biology, a range of combination treatment approaches are being actively investigated to further improve the clinical outcomes of the disease. These combinations, which involve DNA-damaging agents, targeted therapies of signaling pathways and immunotherapies, simultaneously target multiple cancer pathways or hallmarks to induce additive or synergistic antitumor activities. Here we review the preclinical data and ongoing clinical trials for developing effective combination therapies in treating ovarian cancer. These emerging therapeutic modalities may reshape the treatment landscape of the disease.

Bioinformatics Probing of Tissue-Specific MiRNAs Overexpressed in Active Tuberculosis Reveals Induction of Multiple Cancer Pathways

2018 ◽  
Vol 07 (03) ◽  
Author(s):  
Elvis Ndukong Ndzi ◽  
Ambily Nath ◽  
Achuthsankar S Nair ◽  
Chellappan V Biju ◽  
Shidhi PR ◽  
...  
Keyword(s):  
Active Tuberculosis ◽  
Multiple Cancer ◽  
Tissue Specific ◽  
Cancer Pathways

scholarly journals CircEIF4G2 Promotes Tumorigenesis and Progression of Osteosarcoma by Sponging miR-218

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Erhu Lin ◽  
Shuai Liu ◽  
Wei Xiang ◽  
Hongbo Zhang ◽  
Chaofan Xie
Keyword(s):  
Signaling Pathway ◽  
Migration And Invasion ◽  
Circular Rnas ◽  
Loss Of Function ◽  
Multiple Cancer ◽  
Cancer Pathways ◽  
Egfr Signaling Pathway ◽  
Potential Biomarker ◽  
Erbb Signaling ◽  
Tumorigenesis And Progression

Circular RNAs (circRNAs) play a key role in regulating the tumorigenesis and development of human cancers, including osteosarcoma (OS). Of note, the molecular mechanism underlying the progression of OS has remained largely unclear. The present study identified that a novel circRNA circEIF4G2 was upregulated in OS tissues and cells. Moreover, we constructed a circEIF4G2-mediated ceRNA network and revealed that circEIF4G2 was involved in regulating multiple cancer pathways, such as the EGFR signaling pathway, the PI3K-Akt signaling pathway, and the ErbB signaling pathway. Loss-of-function assays showed that circEIF4G2 knockdown significantly suppressed OS cell proliferation, migration, and invasion. Mechanically, we found that circEIF4G2 could directly bind to miR-218, and miR-218 mediated the effect of circEIF4G2 knockdown on OS progression. In conclusion, the present study showed that circEIF4G2 could be a potential biomarker for OS.

scholarly journals RNA-based therapies: A cog in the wheel of lung cancer defense

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Parvez Khan ◽  
Jawed Akhtar Siddiqui ◽  
Imayavaramban Lakshmanan ◽  
Apar Kishor Ganti ◽  
Ravi Salgia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Great Promise ◽  
Therapeutic Approaches ◽  
Small Cell Lung ◽  
Multiple Cancer ◽  
Acquired Drug Resistance ◽  
Cancer Pathways

AbstractLung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the identification and development of innovative and effective therapeutic approaches are critically desired for LC. The development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies that have translational potential for LC therapies.

scholarly journals miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs

2013 ◽  
Vol 4 ◽  
Author(s):  
Laura Lupini ◽  
Cristian Bassi ◽  
Manuela Ferracin ◽  
Nenad Bartonicek ◽  
Lucilla D'Abundo ◽  
...  
Keyword(s):  
Messenger Rnas ◽  
Multiple Cancer ◽  
Cancer Pathways

scholarly journals Resource optimization for cancer pathways with aggregate diagnostic demand: a perishable inventory approach

2020 ◽  
Author(s):  
Edilson F Arruda ◽  
Paul Harper ◽  
Tracey England ◽  
Daniel Gartner ◽  
Emma Aspland ◽  
...  
Keyword(s):  
Diagnostic Test ◽  
Diagnostic Tests ◽  
Aggregate Demand ◽  
Random Variable ◽  
Inventory Problem ◽  
Multiple Cancer ◽  
Perishable Inventory ◽  
Cancer Pathways ◽  
Queuing Models ◽  
Cancer Services

Abstract This work proposes a novel framework for planning the capacity of diagnostic tests in cancer pathways that considers the aggregate demand of referrals from multiple cancer specialties (sites). The framework includes an analytic tool that recursively assesses the overall daily demand for each diagnostic test and considers general distributions for both the incoming cancer referrals and the number of required specific tests for any given patient. By disaggregating the problem with respect to each diagnostic test, we are able to model the system as a perishable inventory problem that can be solved by means of generalized G/D/C queuing models, where the capacity $C$ is allowed to vary and can be seen as a random variable that is adjusted according to prescribed performance measures. The approach aims to provide public health and cancer services with recommendations to align capacity and demand for cancer diagnostic tests effectively and efficiently. Our case study illustrates the applicability of our methods on lung cancer referrals from UK’s National Health Service.

Sign in / Sign up

Export Citation Format

Share Document